We are pioneering the discovery and development of precision medicines for non-genetic and polygenic (“sporadic”) neurodegenerative disorders.

Mosaic drives cutting-edge, cross-ecosystem R&D into innovative disease models and AI — and then use the advances to accelerate our partners’ precision medicine programs. As a public benefit innovation engine, profits are reinvested in the research ecosystem and distributed to our stakeholders and investors.